Stevenage, United Kingdom, December 1, 2025 NRG Therapeutics has announced the appointment of Dr. Paul Thompson as Chief Development Officer (CDO), marking a strategic expansion ahead of the company’s transition into first-in-human studies for its lead candidate, NRG5051, in early 2026. The company, a neuroscience-focused biopharmaceutical innovator targeting mitochondrial dysfunction, continues to build momentum following its £50 million Series B financing, strengthening its leadership team as it advances toward clinical proof-of-concept studies in ALS/MND and Parkinson’s disease.
Science Significance
The appointment of Dr. Thompson carries significant scientific weight for NRG’s mission to develop first-in-class inhibitors of the mitochondrial permeability transition pore (mPTP). NRG5051, an oral, CNS-penetrant small molecule, has demonstrated profound neuroprotective and anti-inflammatory effects in preclinical models of ALS/MND and Parkinson’s, validating its novel mechanism of action. Dr. Thompson’s extensive background in neurology and translational research, including his leadership of USP30 inhibitor projects and publications in Nature journals, strengthens the company’s scientific leadership as NRG5051 moves from IND-enabling stages to clinical evaluation. His experience integrating biomarker science, neurodegenerative disease mechanisms, and early clinical development bolsters NRG’s capacity to advance mitochondrial therapeutics grounded in rigorous mechanistic evidence.
Regulatory Significance
With NRG5051 on track to enter first-in-human trials in early 2026, the addition of a seasoned development leader is strategically aligned with NRG’s regulatory trajectory. Dr. Thompson brings deep experience navigating IND preparation, Phase 1 trial execution, and early-phase regulatory strategy, particularly for CNS and mitochondrial programs. His leadership is poised to enhance NRG’s ability to meet evolving regulatory expectations for neurodegenerative-disease biomarkers, safety assessments, and mechanism-based evidence. As NRG prepares for Phase 1 and future Phase 2 studies, his expertise supports the alignment of clinical-trial design, regulatory submissions, and long-term development planning across multiple indications.
Business Significance
Advertisement
NRG’s leadership expansion follows its substantial £50 million Series B raise, which provides runway to support clinical proof-of-concept development in ALS/MND and exploration of therapeutic potential in Parkinson’s disease Dr. Thompson’s appointment strengthens operational capacity as the company grows to 12 employees, including its founders. His record of advancing assets into Phase 1 trials, engaging with patient-advocacy funders such as the Michael J. Fox Foundation, and supporting biotech-stage growth positions NRG to efficiently leverage its financing for development milestones. The appointment enhances the company’s business readiness for partnerships, clinical-stage scaling, and investor expectations tied to advancing a first-in-class therapeutic platform.
Patients’ Significance
For patients living with ALS/MND and Parkinson’s disease, therapeutic options remain severely limited, with few disease-modifying treatments available. Preclinical evidence that NRG5051 reduces neuroinflammation, preserves neuronal integrity, and lowers neurofilament light chain (NfL)—a clinically validated biomarker of neurodegeneration—offers a promising signal for patients in urgent need of breakthrough innovations. Dr. Thompson’s commitment to advancing the therapy as a potential first disease-modifying approach could accelerate the path to clinical benefit. His expertise in early-stage CNS drug development enhances the likelihood of rigorous, patient-centered trial designs that support safer and more effective therapeutic outcomes.
Policy Significance
The expansion of NRG’s leadership aligns with national and international policy priorities promoting innovation in neurodegenerative-disease research, mitochondrial dysfunction, and biotech translational science. As regulatory bodies and public-funding organizations emphasize biomarker-based development and targeted mechanisms for neurological conditions, NRG’s advancement of a novel mPTP inhibitor resonates with broader health-policy objectives. The company’s support from organizations such as Parkinson’s UK, Target ALS, Innovate UK, and the Michael J. Fox Foundation reflects strong alignment between public-sector priorities and private-sector innovation. Strengthening its executive leadership enhances its ability to meet future compliance requirements, secure funding, and align development strategies with emerging policy frameworks.
NRG Therapeutics’ appointment of Dr. Paul Thompson as Chief Development Officer marks a pivotal moment as the company prepares to move its breakthrough mPTP-inhibitor program into clinical testing. With robust financing, expanding leadership, and compelling preclinical evidence, NRG is poised to accelerate the development of NRG5051 as a potential disease-modifying therapy for ALS/MND, Parkinson’s, and other neurodegenerative disorders. The addition of a proven scientific leader underscores NRG’s commitment to advancing innovative mitochondrial therapeutics and shaping the future landscape of neurodegenerative-disease treatment.
Source: NRG Therapeutics Ltd. press release
